TrialBritish journal of cancer2017

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.

Adil Daud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.